報價延遲最少15分鐘:2025/01/21 05:39 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3775 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.06/--
|
|
企業價值
6.93M
|
| 資產負債 |
|
每股賬面淨值
0.52
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.77M
|
|
每股收益
0.58
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 05:39 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the earlydetection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases. |